Testing version — LOERadar is in active testing. Features and data may change.
SERZONE (NEFAZODONE HYDROCHLORIDE) | LOERadar
SERZONE
NDA
NEFAZODONE HYDROCHLORIDE | N020152 | BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
6 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (6)
Sort:
#001 — 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
TABLET;ORAL | Approved: Dec 22, 1994
No patent or exclusivity listings for this strength.
#002 — 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Dec 22, 1994
#003 — 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Dec 22, 1994
#004 — 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Dec 22, 1994
#005 — 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET;ORAL | Approved: Dec 22, 1994
#006 — 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**